Riley Farley

Despite experienced teams and best intentions, many research networks find themselves stuck in the same cycle: late feasibility responses, fragmented communication, and missed activation milestones. The early stages of a trial – feasibility, site selection, and activation – are where timelines are won or lost. For large networks managing multiple locations and therapeutic areas, coordinating … Read more

The funding landscape for clinical trials is undergoing a significant transformation. As grant support for NIH-funded studies continues to decline, clinical research sites and CROs are facing growing pressure to identify alternative sources of revenue. Increasingly, that source is the pharmaceutical industry. Making the transition from NIH-funded to pharmaceutical-funded trials requires a deliberate focus on … Read more

Clinical research sites are at a crossroads. The demand for efficiency, transparency, and accountability has never been higher, yet many sites still struggle with fragmented processes, disconnected data, and inefficient workflows. The question isn’t whether data is available but how sites can harness it effectively to improve operations, attract sponsors, and ultimately win more studies … Read more